PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News:
STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing the world’s first and only Self-Apposing® coronary stent, today announces that the results of the APPOSITION IV trial, which compared the STENTYS Self-Apposing Sirolimus-eluting coronary stent to the Medtronic Resolute® stent in patients presenting with ST-segment elevation myocardial infarction (STEMI), were published in the February issue of EuroIntervention, the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
